Our Pipeline
Our goal is the generation of novel vaccines to treat and prevent chronic diseases.
Based on our WISIT technology platform, we are advancing a broad and diverse pipeline focusing on chronic diseases amenable to antibody therapy.
We design best-in-class vaccine candidates eliciting antibody levels that fall within the range of those obtained with monoclonal antibodies (“intrinsic antibody therapy”).
The focus of our Phase 1B program in Parkinson’s disease (NCT07777484, NCT07840027) is demonstrating safety and target engagement.
| IndicationTarget | Target | Pipeline | |||
|---|---|---|---|---|---|
DiscoveryPOC*/PreclinicalPhase 1Phase 2 | |||||
| Parkinson’s Diseasepathologic αSyn | pathologic αSyn | ||||
| PrurigoIL31 | IL31 | ||||
| PsoriasisCytokine | Cytokine | ||||
| Alzheimer’s DiseaseAβ | Aβ | ||||
| ASCVDPCSK9 | PCSK9 | ||||
- *… POC/Preclinical includes in vivo Proof of Concept and preclinical development required for IND filing